Are adipocytokines inflammatory or metabolic mediators in patients with inflammatory bowel disease?

dc.contributor.author	Kahraman, R.
dc.contributor.author	Calhan, T.
dc.contributor.author	Sahin, A.
dc.contributor.author	Ozdil, K.
dc.contributor.author	Caliskan, Z.
dc.contributor.author	Bireller, E.S.
dc.contributor.author	Cakmakoglu, B.
dc.date.accessioned	2021-12-21T08:41:13Z
dc.date.available	2021-12-21T08:41:13Z
dc.date.issued	2017
dc.identifier.issn	11766336
dc.identifier.uri	https://doi.org/10.2147/TCRM.S140618
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1359
dc.description.abstract	This study examined the adiponectin and leptin levels and insulin resistance (IR) in patients with inflammatory bowel disease (IBD) and the associations between these factors and IBD characteristics. Fasting serum leptin, adiponectin, glucose, and insulin
dc.language.iso	English
dc.publisher	Dove Medical Press Ltd.
dc.rights	All Open Access, Gold, Green
dc.title	Are adipocytokines inflammatory or metabolic mediators in patients with inflammatory bowel disease?
dc.type	Article
dc.relation.journal	Therapeutics and Clinical Risk Management
dc.identifier.startpage	1295
dc.identifier.endpage	1301
dc.identifier.volume	13
dc.identifier.doi	10.2147/TCRM.S140618
dc.relation.volume	13